Table 3.
Among Subjects With Prior Cranial Irradiation, Growth Hormone Treatment Exposure and the Adjusted Rate Ratios for Meningioma and Glioma as Second Neoplasms, Stratified by Radiation Dose to the Brain (Multivariate)a
| Meningioma RR (95% CI) |
Glioma RR (95% CI) |
|||
|---|---|---|---|---|
| RR (95% CI) | P Value | RR (95% CI) | P Value | |
| Prior cranial radiation ≤45 Gy | ||||
| No GH treatment (n = 3136) | 1 | .8 | 1 | .93 |
| GH treatment (n = 131) | 0.8 (0.2–3.5) | 1.1 (0.1–8.4) | ||
| Prior cranial radiation >45 Gy | ||||
| No GH treatment (n = 838) | 1 | .52 | 1 | .23 |
| GH treatment (n = 172) | 0.8 (0.3–1.7) | 2.1 (0.6–7.4) | ||
a
Adjusted for age at the follow-up, sex, age at primary diagnosis, CRT/time since CRT radiation (time dependent), intrathecal methotrexate, estrogen and/or progesterone treatment (time dependent), and alkylating agents (yes/no). GH treatment is the time-dependent variable.